$49.25
2.03% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Rhythm Pharmaceuticals, Inc. Stock price

$49.25
+5.21 11.83% 1M
+8.15 19.83% 6M
+3.28 7.14% YTD
+23.64 92.31% 1Y
+36.30 280.31% 3Y
+28.74 140.13% 5Y
+19.25 64.17% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.98 2.03%
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Key metrics

Market capitalization $3.01b
Enterprise Value $2.94b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 28.93
P/S ratio (TTM) P/S ratio 29.58
P/B ratio (TTM) P/B ratio 76.48
Revenue growth (TTM) Revenue growth 132.57%
Revenue (TTM) Revenue $101.78m
EBIT (operating result TTM) EBIT $-265.58m
Free Cash Flow (TTM) Free Cash Flow $-128.45m
Cash position $319.13m
EPS (TTM) EPS $-4.37
P/E forward negative
P/S forward 24.62
EV/Sales forward 24.07
Short interest 24.49%
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Rhythm Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
102 102
133% 133%
100%
- Direct Costs 12 12
100% 100%
12%
90 90
138% 138%
88%
- Selling and Administrative Expenses 132 132
30% 30%
130%
- Research and Development Expense 222 222
92% 92%
218%
-264 -264
48% 48%
-259%
- Depreciation and Amortization 1.76 1.76
4% 4%
2%
EBIT (Operating Income) EBIT -266 -266
47% 47%
-261%
Net Profit -259 -259
42% 42%
-255%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Positive
Investors Business Daily
one day ago
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.
Positive
Seeking Alpha
9 days ago
Rhythm Pharmaceuticals' Q2 revenue rose to $29.1 million, driven by global sales of Imcivree, its treatment for rare genetic obesity disorders. The company's cash and investments totaled $319 million by June 30, 2024, ensuring a cash runway into 2026, according to Rhythm's projections. Imcivree is currently undergoing a Phase 3 trial for hypothalamic obesity, with results expected in 1H 2025, c...
Neutral
GlobeNewsWire
12 days ago
-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- -- FDA sets PDUFA goal date of December 26, 2024 --
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Employees 226
Founded 2008
Website www.rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today